Emerging therapies and respiratory infections: Focus on the impact of immunosuppressants and immunotherapies

Caroline M Patterson; Timothy D Shaw; Vicky Gerovasili; Usman Khatana; Ricardo J Jose

doi:10.1016/j.clinme.2024.100015

Emerging therapies and respiratory infections: Focus on the impact of immunosuppressants and immunotherapies

Clin Med (Lond). 2024 Jan;24(1):100015. doi: 10.1016/j.clinme.2024.100015. Epub 2024 Jan 17.

Authors

Caroline M Patterson¹, Timothy D Shaw², Vicky Gerovasili³, Usman Khatana⁴, Ricardo J Jose⁵

Affiliations

¹ Consultant in Respiratory Transplant Medicine, Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK. Electronic address: [email protected].
² Academic Clinical Lecturer in Infectious Diseases and Medical Microbiology, Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, Belfast, UK.
³ Consultant in Respiratory Transplant Medicine, Royal Brompton and Harefield hospital, part of Guys and St Thomas NHS Foundation trust, London, UK.
⁴ Specialty Trainee in Respiratory Medicine, Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK.
⁵ Consultant in Host Defence, Royal Brompton and Harefield hospital, part of Guys and St Thomas NHS Foundation trust, London, UK.

Abstract

Host defences to infection are based upon an integrated system of physical and biochemical barriers, innate and adaptive immunity. Weakness in any of these defensive elements leads to increased susceptibility to specific pathogens. Understanding how medical therapies disrupt host defences is key to the successful prevention, diagnosis and management of respiratory infection in the immunocompromised host.

Keywords: Immunosupression; Immunotherapy; Respiratory infection.

Publication types

Review

MeSH terms

Adaptive Immunity
Humans
Immunocompromised Host
Immunosuppressive Agents* / therapeutic use
Immunotherapy
Respiratory Tract Infections* / drug therapy

Substances

Immunosuppressive Agents

Grants and funding

MR/R017867/1/MRC_/Medical Research Council/United Kingdom